tirzepatide pancreatitis gallbladder disease risk GLP-1 receptor agonists and risk: insights into molecular mechanisms and clinical implications Tirzepatide and Pancreatitis Risk: What

Tirzepatide significantly outperformed dulaglutide, semaglutide, degludec, and glargine in terms of its effects on postprandial and fasting blood glucose levels as well as the likelihood that patients using it would experience a decrease in HbA1c [8-10]

Gerstein HC, Colhoun HM, Dagenais GR, et al

Among these participants, males comprised 729 individuals, comprising 55.1% of the total population

If it remains severe or occurs multiple times a week beyond the eight-week mark, discuss anti-nausea medication or a dose reduction with your prescriber

Quality assessment No formal quality scoring tool (e.g., NOS or GRADE) was applied, given the heterogeneity of included study designs